Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Lourdes Anta; Josep M. Llibre; Eva Poveda; José L. Blanco; Marta Álvarez; María J. Pérez-Elías; Antonio Aguilera; Estrella Caballero; Vicente Soriano; Carmen De Mendoza; J. A. Iribarren; J. M. Gatell; E. Ribera; J. Martínez-Picado; B. Clotet; A. Jaén; D. Dalmau; J. Peraire; C. Vidal; M. Riera; J. Córdoba; J. López-Aldeguer; M. J. Galindo; C. Robledano; F. Gutiérrez; M. Álvarez; F. García; I. Viciana; J. Santos; P. Pérez-Romero; M. Leal; J. A. Pineda; F. Fernández-Cuenca; C. Rodríguez; J. Del Romero; L. Menéndez-Arias; C. Gutiérrez; S. Moreno; M. Pérez-Olmeda; J. Alcamí; A. Cañizares; J. Pedreira; C. Miralles; A. Ocampo; L. Morano; J. J. Rodríguez-Calviño; J. L. Gómez-Sirvent

doi:10.1097/QAD.0b013e3283584500

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Lourdes Anta, Josep M. Llibre, Eva Poveda, José L. Blanco, Marta Álvarez, María J. Pérez-Elías, Antonio Aguilera, Estrella Caballero, Vicente Soriano, Carmen De Mendoza, J. A. Iribarren, J. M. Gatell, E. Ribera, J. Martínez-Picado, B. Clotet, A. Jaén, D. Dalmau, J. Peraire, C. Vidal, M. RieraJ. Córdoba, J. López-Aldeguer, M. J. Galindo, C. Robledano, F. Gutiérrez, M. Álvarez, F. García, I. Viciana, J. Santos, P. Pérez-Romero, M. Leal, J. A. Pineda, F. Fernández-Cuenca, C. Rodríguez, J. Del Romero, L. Menéndez-Arias, C. Gutiérrez, S. Moreno, M. Pérez-Olmeda, J. Alcamí, A. Cañizares, J. Pedreira, C. Miralles, A. Ocampo, L. Morano, J. J. Rodríguez-Calviño, J. L. Gómez-Sirvent

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

56 Cites (Scopus)

Resum

© 2012 Wolters Kluwer Health - Lippincott Williams & Wilkins. Objective: Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs. Methods: RPV RAMs were examined in plasma samples collected from HIV patients that had recently failed NNRTI-based regimens at 22 clinics in Spain. Results: Resistance tests from a total of 1064 patients failing efavirenz (EFV) (54.5%), nevirapine (NVP) (40%) or etravirine (ETR) (5.5%) were examined. The prevalence of RPV RAMs was K101E (9.1%), K101P (1.4%), E138A (3.9%), E138G (0.3%), E138K (0.3%), E138Q (0.8%), V179L (0.2%), Y181C (21.8%), Y181I (0.5%), Y181V (0.2%), H221Y (8.3%), F227C (0.1%) and M230L (1.5%). K101E/M184I was seen in 1%. E138K/M184I were absent. Mutations L100I and V108I were significantly more frequent in patients failing EFV than NVP (7.9 vs. 0.2 and 12.2 vs. 7.3%, respectively). Conversely, Y181C, Y181I, V106A, H221Y and F227L were more prevalent following NVP than EFV failures. Using the Spanish resistance interpretation algorithm, 206 genotypes (19.3%) from patients failing NNRTI (NVP 52%, EFV 40.8% and ETR 7.8%) were considered as RPV resistant. In patients with ETR failure, cross-resistance to RPVwas seen in 27.6%,mainly as result of Y181C (81.3%), V179I (43.8%), V90I (31.3%) and V108I (18.8%). Conclusion: RPV resistance is overall recognized in nearly 20% of patients failing other NNRTIs. It is more common following ETR (27.6%) or NVP (25%) failures than EFV (14.5%). E138 mutants are rarely seen in this context.

Idioma original	Anglès
Pàgines (de-a)	81-85
Revista	AIDS
Volum	27
Número	1
DOIs	https://doi.org/10.1097/QAD.0b013e3283584500
Estat de la publicació	Publicada - 2 de gen. 2013

SDG de les Nacions Unides

Aquest resultat contribueix als següents objectius de desenvolupament sostenible.

Accés al document

10.1097/QAD.0b013e3283584500

Altres arxius i enllaços

https://www.scopus.com/pages/publications/84871618383

Com citar-ho

Anta, L., Llibre, J. M., Poveda, E., Blanco, J. L., Álvarez, M., Pérez-Elías, M. J., Aguilera, A., Caballero, E., Soriano, V., De Mendoza, C., Iribarren, J. A., Gatell, J. M., Ribera, E., Martínez-Picado, J., Clotet, B., Jaén, A., Dalmau, D., Peraire, J., Vidal, C., ... Gómez-Sirvent, J. L. (2013). Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS, 27(1), 81-85. https://doi.org/10.1097/QAD.0b013e3283584500

@article{7184a82e9a3744b8b02543d52e6e42cd,

title = "Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies",

abstract = "{\textcopyright} 2012 Wolters Kluwer Health - Lippincott Williams \& Wilkins. Objective: Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs. Methods: RPV RAMs were examined in plasma samples collected from HIV patients that had recently failed NNRTI-based regimens at 22 clinics in Spain. Results: Resistance tests from a total of 1064 patients failing efavirenz (EFV) (54.5\%), nevirapine (NVP) (40\%) or etravirine (ETR) (5.5\%) were examined. The prevalence of RPV RAMs was K101E (9.1\%), K101P (1.4\%), E138A (3.9\%), E138G (0.3\%), E138K (0.3\%), E138Q (0.8\%), V179L (0.2\%), Y181C (21.8\%), Y181I (0.5\%), Y181V (0.2\%), H221Y (8.3\%), F227C (0.1\%) and M230L (1.5\%). K101E/M184I was seen in 1\%. E138K/M184I were absent. Mutations L100I and V108I were significantly more frequent in patients failing EFV than NVP (7.9 vs. 0.2 and 12.2 vs. 7.3\%, respectively). Conversely, Y181C, Y181I, V106A, H221Y and F227L were more prevalent following NVP than EFV failures. Using the Spanish resistance interpretation algorithm, 206 genotypes (19.3\%) from patients failing NNRTI (NVP 52\%, EFV 40.8\% and ETR 7.8\%) were considered as RPV resistant. In patients with ETR failure, cross-resistance to RPVwas seen in 27.6\%,mainly as result of Y181C (81.3\%), V179I (43.8\%), V90I (31.3\%) and V108I (18.8\%). Conclusion: RPV resistance is overall recognized in nearly 20\% of patients failing other NNRTIs. It is more common following ETR (27.6\%) or NVP (25\%) failures than EFV (14.5\%). E138 mutants are rarely seen in this context.",

keywords = "drug resistance, efavirenz, etravirine, nevirapine, rilpivirine",

author = "Lourdes Anta and Llibre, \{Josep M.\} and Eva Poveda and Blanco, \{Jos{\'e} L.\} and Marta {\'A}lvarez and P{\'e}rez-El{\'i}as, \{Mar{\'i}a J.\} and Antonio Aguilera and Estrella Caballero and Vicente Soriano and \{De Mendoza\}, Carmen and Iribarren, \{J. A.\} and Gatell, \{J. M.\} and E. Ribera and J. Mart{\'i}nez-Picado and B. Clotet and A. Ja{\'e}n and D. Dalmau and J. Peraire and C. Vidal and M. Riera and J. C{\'o}rdoba and J. L{\'o}pez-Aldeguer and Galindo, \{M. J.\} and C. Robledano and F. Guti{\'e}rrez and M. {\'A}lvarez and F. Garc{\'i}a and I. Viciana and J. Santos and P. P{\'e}rez-Romero and M. Leal and Pineda, \{J. A.\} and F. Fern{\'a}ndez-Cuenca and C. Rodr{\'i}guez and \{Del Romero\}, J. and L. Men{\'e}ndez-Arias and C. Guti{\'e}rrez and S. Moreno and M. P{\'e}rez-Olmeda and J. Alcam{\'i} and A. Ca{\~n}izares and J. Pedreira and C. Miralles and A. Ocampo and L. Morano and Rodr{\'i}guez-Calvi{\~n}o, \{J. J.\} and G{\'o}mez-Sirvent, \{J. L.\}",

year = "2013",

month = jan,

day = "2",

doi = "10.1097/QAD.0b013e3283584500",

language = "English",

volume = "27",

pages = "81--85",

number = "1",

}

Anta, L, Llibre, JM, Poveda, E, Blanco, JL, Álvarez, M, Pérez-Elías, MJ, Aguilera, A, Caballero, E, Soriano, V, De Mendoza, C, Iribarren, JA, Gatell, JM, Ribera, E, Martínez-Picado, J, Clotet, B, Jaén, A, Dalmau, D, Peraire, J, Vidal, C, Riera, M, Córdoba, J, López-Aldeguer, J, Galindo, MJ, Robledano, C, Gutiérrez, F, Álvarez, M, García, F, Viciana, I, Santos, J, Pérez-Romero, P, Leal, M, Pineda, JA, Fernández-Cuenca, F, Rodríguez, C, Del Romero, J, Menéndez-Arias, L, Gutiérrez, C, Moreno, S, Pérez-Olmeda, M, Alcamí, J, Cañizares, A, Pedreira, J, Miralles, C, Ocampo, A, Morano, L, Rodríguez-Calviño, JJ & Gómez-Sirvent, JL 2013, 'Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies', AIDS, vol. 27, núm. 1, pàg. 81-85. https://doi.org/10.1097/QAD.0b013e3283584500

TY - JOUR

T1 - Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

AU - Anta, Lourdes

AU - Llibre, Josep M.

AU - Poveda, Eva

AU - Blanco, José L.

AU - Álvarez, Marta

AU - Pérez-Elías, María J.

AU - Aguilera, Antonio

AU - Caballero, Estrella

AU - Soriano, Vicente

AU - De Mendoza, Carmen

AU - Iribarren, J. A.

AU - Gatell, J. M.

AU - Ribera, E.

AU - Martínez-Picado, J.

AU - Clotet, B.

AU - Jaén, A.

AU - Dalmau, D.

AU - Peraire, J.

AU - Vidal, C.

AU - Riera, M.

AU - Córdoba, J.

AU - López-Aldeguer, J.

AU - Galindo, M. J.

AU - Robledano, C.

AU - Gutiérrez, F.

AU - Álvarez, M.

AU - García, F.

AU - Viciana, I.

AU - Santos, J.

AU - Pérez-Romero, P.

AU - Leal, M.

AU - Pineda, J. A.

AU - Fernández-Cuenca, F.

AU - Rodríguez, C.

AU - Del Romero, J.

AU - Menéndez-Arias, L.

AU - Gutiérrez, C.

AU - Moreno, S.

AU - Pérez-Olmeda, M.

AU - Alcamí, J.

AU - Cañizares, A.

AU - Pedreira, J.

AU - Miralles, C.

AU - Ocampo, A.

AU - Morano, L.

AU - Rodríguez-Calviño, J. J.

AU - Gómez-Sirvent, J. L.

PY - 2013/1/2

Y1 - 2013/1/2

N2 - © 2012 Wolters Kluwer Health - Lippincott Williams & Wilkins. Objective: Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs. Methods: RPV RAMs were examined in plasma samples collected from HIV patients that had recently failed NNRTI-based regimens at 22 clinics in Spain. Results: Resistance tests from a total of 1064 patients failing efavirenz (EFV) (54.5%), nevirapine (NVP) (40%) or etravirine (ETR) (5.5%) were examined. The prevalence of RPV RAMs was K101E (9.1%), K101P (1.4%), E138A (3.9%), E138G (0.3%), E138K (0.3%), E138Q (0.8%), V179L (0.2%), Y181C (21.8%), Y181I (0.5%), Y181V (0.2%), H221Y (8.3%), F227C (0.1%) and M230L (1.5%). K101E/M184I was seen in 1%. E138K/M184I were absent. Mutations L100I and V108I were significantly more frequent in patients failing EFV than NVP (7.9 vs. 0.2 and 12.2 vs. 7.3%, respectively). Conversely, Y181C, Y181I, V106A, H221Y and F227L were more prevalent following NVP than EFV failures. Using the Spanish resistance interpretation algorithm, 206 genotypes (19.3%) from patients failing NNRTI (NVP 52%, EFV 40.8% and ETR 7.8%) were considered as RPV resistant. In patients with ETR failure, cross-resistance to RPVwas seen in 27.6%,mainly as result of Y181C (81.3%), V179I (43.8%), V90I (31.3%) and V108I (18.8%). Conclusion: RPV resistance is overall recognized in nearly 20% of patients failing other NNRTIs. It is more common following ETR (27.6%) or NVP (25%) failures than EFV (14.5%). E138 mutants are rarely seen in this context.

AB - © 2012 Wolters Kluwer Health - Lippincott Williams & Wilkins. Objective: Rilpivirine (RPV) is the latest approved nonnucleoside reverse transcriptase inhibitor (NNRTI). It displays in-vitro activity extending over other NNRTI-resistant HIV strains. There is scarce information about the rate of RPV resistance-associated mutations (RAMs) in patients failing other NNRTIs. Methods: RPV RAMs were examined in plasma samples collected from HIV patients that had recently failed NNRTI-based regimens at 22 clinics in Spain. Results: Resistance tests from a total of 1064 patients failing efavirenz (EFV) (54.5%), nevirapine (NVP) (40%) or etravirine (ETR) (5.5%) were examined. The prevalence of RPV RAMs was K101E (9.1%), K101P (1.4%), E138A (3.9%), E138G (0.3%), E138K (0.3%), E138Q (0.8%), V179L (0.2%), Y181C (21.8%), Y181I (0.5%), Y181V (0.2%), H221Y (8.3%), F227C (0.1%) and M230L (1.5%). K101E/M184I was seen in 1%. E138K/M184I were absent. Mutations L100I and V108I were significantly more frequent in patients failing EFV than NVP (7.9 vs. 0.2 and 12.2 vs. 7.3%, respectively). Conversely, Y181C, Y181I, V106A, H221Y and F227L were more prevalent following NVP than EFV failures. Using the Spanish resistance interpretation algorithm, 206 genotypes (19.3%) from patients failing NNRTI (NVP 52%, EFV 40.8% and ETR 7.8%) were considered as RPV resistant. In patients with ETR failure, cross-resistance to RPVwas seen in 27.6%,mainly as result of Y181C (81.3%), V179I (43.8%), V90I (31.3%) and V108I (18.8%). Conclusion: RPV resistance is overall recognized in nearly 20% of patients failing other NNRTIs. It is more common following ETR (27.6%) or NVP (25%) failures than EFV (14.5%). E138 mutants are rarely seen in this context.

KW - drug resistance

KW - efavirenz

KW - etravirine

KW - nevirapine

KW - rilpivirine

UR - https://www.scopus.com/pages/publications/84871618383

U2 - 10.1097/QAD.0b013e3283584500

DO - 10.1097/QAD.0b013e3283584500

M3 - Article

SN - 0269-9370

VL - 27

SP - 81

EP - 85

JO - AIDS

JF - AIDS

IS - 1

ER -

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

Resum

SDG de les Nacions Unides

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho